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As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we
performed a retrospective analysis of patients seen at Washington University in
St. Louis to evaluate whether it benefited our patient population. Patients were
risk-assessed using the Memorial Sloan Kettering Predictive Nomogram
(MSKPN). We defined high-risk patients by a MSKPN 4-year postoperative
probability of sarcoma-specific death of ≥0.3 and investigated if they benefited
from AC. Retrospective review was performed on patients seen between 15 Feb-
ruary 1996 and 6 February 2010. A propensity score method in the logistic
regression framework was used to model the likelihood of receiving AC. To
make causal inference on the effect of AC on survival outcomes, a propensity
score inverse probability of treatment weighting approach was applied to sur-
vival analysis. Overall, 135 high-grade patients were assessed, 33 were treated
with Ifosfamide/Epirubicin (I/Epi) and 102 were non AC patients. The stratified
MSKPN risk was not significantly associated with any survival endpoint in the
whole cohort, but trended for overall survival (OS) when evaluated against non
AC patients. After adjustment for MSKPN risk and other variables, patients not
receiving chemotherapy had significantly worse OS, recurrent free survival, and
disease-specific survival (DSS) with adjusted hazard ratios of 4.18 (95% CI:
2.22–7.90), 8.96 (95% CI: 3.85–20.83), and 5.42 (95% CI: 2.09–14.06), respec-
tively. In retrospective analyses, risk-stratified patients with soft tissue sarcoma
benefited from I/Epi-based AC. Randomized I/Epi versus I/Doxorubicin clinical
trials may determine the optimal adjuvant treatment.
Introduction
Soft tissue sarcomas (STS) are cancers of mesenchymal
origin with an US annual incidence of approximately
11,000 per year [1]. The treatment of nonmetastatic sar-
coma includes en bloc resection with or without radiation
depending on grade, histology, size, and margin status
[2]. When combined with adjuvant radiotherapy, extrem-
ity STS have shown improved 5-year disease-free survival
(DFS) up to 22% [3, 4]. Due to molecular heterogeneity,
the role of neoadjuvant and adjuvant chemotherapy (AC)
remains controversial, albeit commonly used by some
institutions as standard of care.
A Cochrane systematic review of 14 clinical trials
including all primary sites confirmed reduction in
recurrence, improved DFS, and trend toward OS for
anthracycline-based AC groups [5]. A second systematic
meta-analysis of 17 randomized controlled trials of
patients receiving AC had recurrent free survival (RFS)
and OS benefit found to be greatest within combination
Ifosfamide/Epirubicin (I/Epi) trials [6]. The most com-
pelling trial for the use of AC to prevent recurrence was
by Italian Sarcoma Study Group, which demonstrated a
5-year OS probability of 0.66 versus 0.46 for adjuvant I/
Epi and control groups, respectively [7]. A follow-up
phase III trial using three cycles of neoadjuvant I/Epi
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with or without two additional postoperative cycles saw
benefit with an epirubicin-based regimen demonstrated
a 5-year OS probability of 0.70 [8]. Based on these data,
epirubicin replaced doxorubicin as standard of care for
AC at Washington University
Since all-comer histology sarcoma trials are compli-
cated by the underlying subpopulation heterogeneity,
many nomograms have been developed to support appro-
priate disease management. Over 10 nomograms have
been developed to evaluate and predict survival probabili-
ties, including specific nomograms for histology and site-
of-origin [9–14]. The Memorial Sloan Kettering Predictive
Nomogram (MSKPN) was based on a multivariate Cox
model stratified by histological grade and predicts 4-, 8-,
and 12-year probability of sarcoma-specific death [15,
16]. The MSKPN has been validated by at least three
external populations with a concordance index of 0.67–
0.76 (0.73 average) [17, 18].
Due to the toxicity of AC, we prospectively use
MSKPN in our decision to use AC. Patients with a ≥30%
4-year postoperative probability of sarcoma-specific death
were defined as high risk and were more likely to be
offered AC. We hypothesized that AC (specifically I/Epi)
given to high-risk patients would improve patient survival
and delay recurrence. As such, we have conducted a ret-
rospective study on STS patients seen at Washington Uni-
versity to investigate this hypothesis.
Methods
Patients
With Institutional Review Board approval, we reviewed
the charts of 168 STS patients who were seen by Medical
Oncology at Washington University between 15 February
1996 and 6 February 2010. The most recent follow-up
date was 20 May 2013. Patient selection flowchart is illus-
trated in Figure 1A. Patients who progressed before adju-
vant treatment, had de novo metastatic disease, or had
died from surgical complications were excluded. In 145
high-grade STS patients, 43 received AC (33 I/Epi, 8
doxorubicin/ifosfamide/dacarbazine, 2 taxotere/gemciti-
bine), while 102 received no adjuvant treatment. We
focused on analyzing the 33 patients with adjuvant I/Epi
and the 102 patients who had not received AC. For I/Epi
AC, all patients were given Ifosfamide was given at
1800 mg/m2 over 5 days with epirubicin given at 60 mg/
m2 on the first 2 days of a 3-week cycle. Patients receiv-
ing I/Epi were either chosen for treatment based on a
MSKPN risk assessment of death of >30% at 4 years or
were seen in second opinion where this decision was
independently made.
Statistical analysis
Categorical variables were summarized as counts and per-
centages, and between variable associations were examined
by Fisher’s exact test or X2 test. Continuous variables were
summarized by mean and interquartile range and com-
pared by two-sample t-test. OS and disease-specific
survival (DSS) were defined as the time interval between
date of surgery to date of death or latest follow-up date (20
May 2013). STS disease-specific death, the event indicator
for DSS, was defined if a patient’s death was preceded by a
recurrence or a patient died without a recurrence but with
evidence of disease progression. Recurrence was defined as
local or distant tumor after 6-month post operation disease
free period. RFS was defined as from date of surgery to
date of recurrence, date of death, or latest follow-up. The
Kaplan–Meier (KM) product limit method was used to
estimate empirical survival probabilities. Log-rank test was
performed to compare survival difference between/among
groups and 5-year survival probabilities were estimated
with 95% confidence interval (CI).
The analysis objective was to make causal inference on
the effect of AC on survival endpoints. Due to the limita-
tion of a retrospective study where treatment allocation
was not randomized, it was impossible to determine
whether differences observed in endpoints were due to
treatment. As an alternative, the propensity score method
[19] was adopted to estimate the likelihood of receiving
AC through logistic regression modeling. When subjects
have similar propensity scores, observed covariates are
automatically controlled and difference in endpoints is
attributable to treatment, not observed covariates.
To calculate the propensity scores, the Firth logistic
regression model [20], which handles the issues of separa-
bility, small sample sizes, and bias of the parameter esti-
mates and estimates model parameters by penalized
likelihood method was fit on treatment to derive a full
model that included all available covariates. The backward
selection method was applied to determine the final logis-
tic regression model for treatment selection where all co-
variates with a resulting P-value ≤0.2 were retained. Odds
ratios (OR) and 95% CIs from the logistic regression
model were reported on adjusted influence of variables.
The propensity scores (the probability of receiving an
assigned treatment) were predicted from the final logistic
regression model and the weights on subjects were calcu-
lated as inverse to the propensity scores.
We evaluated the causal effect of AC on the survival
endpoints using the KM method and Cox proportional
hazard model with adjustment for the estimated propen-
sity scores using the propensity score inverse probability
of treatment weighting (IPTW) approach [19], where each
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subject is weighted not by conventional equal weight of 1
but by the propensity score IPTW. The proportional haz-
ard assumption was tested for validity of Cox proportional
hazard model. In logistic regression models and Cox mod-
els, age at diagnosis was considered in its original scale,
and after a cubic spline transformation, only results in the
original scale were reported since both gave similar results.
To provide a P-value for the categorical variable histology,
the likelihood ratio test was conducted comparing the full
(logistic regression or Cox) model against the model leav-
ing histology out. All tests were two-sided, significance
was claimed at the 5% level. The statistical computing
software R (version 2.15.2; R Foundation for Statistical
Computing, Vienna, Austria) [21] was used for statistical
analyses. The R package “logistf” [22] was used for the
Firth logistic regression and “rms” [23] and “survival”
[24] software were used for survival analysis.
Results
Patient population
The demographic and clinical/pathological characteristics
of the 135 patients, overall and by treatment, are summa-
rized in Table 1. The average age of the entire cohort was
55.4(range: 16–89) years. Overall, gender distribution was
balanced (54.1% male patients vs. 45.9% female patients,
one-sample proportion test P = 0.39). The median tumor
size was 7.5 cm with an interquartile range of 5.1–12.4.
Overall, 120 (89%) patients had tumors at a deep ana-
tomic depth with the most common tumor site being
lower extremity (39%).
Seventy-five (56%) patients died while 60 patients
were alive at most recent follow-up. Forty-five patients
(34%) experienced disease recurrence and 32 (71%) died
1 pt do-novo metastasis 
2 neo-adjuvant I/Epi pts
•2 pts with unresectable mass 
•2 pts died of surgery-related complications
168 STS pts
146 STS pts
145 high-grade STS pts 1 low-grade STS pt (ID = 152)
135 STS pts 
(33 I/Epi vs. 102 No-adjuvant)
8 MAID treated & 2 T&G treated
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Figure 1. (A) Consort Diagram (patient exclusion conditions are noted). (B) Boxplot of predicted probability of receiving I/Epi from the final
logistic regression model for treatment assignment. (C) The overall KM curves of OS, RFS and DSS in the original cohort with 95% confidence
intervals (dashed lines) and the number of patients at risk at years 1 15.
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thereafter. Thirty-three patients were deemed as dead from
disease. The median follow-up time was 3.9 years (range:
0.23–14.22 years) and 5.76 years (range: 2.97–14.22 years)
among all patients and the survivors, respectively. The KM
curves of OS, RFS, DSS with 95% CI and total number of
patients at risk for the whole cohort are illustrated
(Fig. 1C), from which the median OS was estimated to be
5.42 years (95% CI: 3.92–7.81) while median RFS and
DSS were not reached. For patients who received no AC,
the median OS, RFS, and DSS were estimated to be
4.05 years (95% CI: 2.75–6.58), 5.43 (95% CI: 2.29-Inf),
and 10.23 years (95% CI: 6.79-Inf), respectively.
Table 1. Summary of patient characteristics overall and by treatment.
Variable Levels
All patients
(N = 135) I/Epi (N = 33)
No-adjuvant
(N = 102)
P-valueCount % Count % Count %
Age at diagnosis Mean (IQR) 55 (46~67) 46 (34~58) 58 (50~68) 0.00030
Tumor size ≤5 34 25 6 18 28 27 0.53
5~10 52 39 15 45 37 36
>10 49 36 12 36 37 36
Depth Deep 120 89 33 100 87 85 0.022
Superficial 15 11 0 0 15 15
Site Lower extremity 53 39 17 52 36 35 0.50
Retro-intra-abdominal 27 20 7 21 20 20
Head and Neck 5 3.7 1 3.0 4 4.0
Thoracic-or-trunk 20 15 2 6.0 18 18
Upper-extremity 13 10 3 9.1 10 10
Visceral 17 13 3 9.1 14 14
Histology Leiomyosarcoma 33 24 6 18 27 26 1.3E-05




42 31 6 18 36 35
Mpnst 13 10 7 21 6 5.9
Other 15 11 0 0 15 15
Synovial 8 6.0 7 21 1 0.98
Fibrosarcoma 2 1.5 0 0 2 2.0
Gender F 62 46 11 33 51 50 0.11
M 73 54 22 67 51 50
Race AA 18 13 3 9.1 15 15 0.55
ASA 3 2.2 0 0 3 2.9
C 114 84 30 91 84 82
Tumor stage T1 22 16 6 18 16 16 0.79
T2 113 84 27 81 86 84
Stage I/II 27 20 5 15 22 22 0.62
III 108 80 28 85 80 78
Margin  67 50 15 45 52 51 0.80
+ 47 35 12 36 35 34
<10 mm 21 16 6 18 15 15
Adjuvant radiation N 50 37 5 15 45 44 0.0033
Y 85 63 28 85 57 56
MSKCC risk Low 63 47 15 45 48 47 1
High 72 53 18 55 54 53
Death Alive 60 44 26 79 34 33 5.8E-06
Death 75 56 7 21 68 67
Recurrence No 86 66 30 94 56 57 7.2E-05
Yes 45 34 2 6.0 43 43
DSS Alive 99 75 31 94 68 69 2.6E-03
Death 33 25 2 6.0 31 31
P-values were derived comparing a variable’s difference between treatment groups. (Fisher’s exact test was used for all except for age (Student’s
t-test)).
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MSKPN predicted risk
We followed the MSKPN [25] definitions of tumor char-
acteristics to categorize variables used in the nomogram.
The demographic and tumor information were input into
the online calculator (http://nomograms.mskcc.org/Sar-
coma/PostSurgery.aspx) [15] and the 4-year postoperative
probability of sarcoma-specific death predicted. The med-
ian 4-year postoperative probability of sarcoma-specific
death in the cohort was 0.31 (range: 0.07–0.8). Seventy-
two patients (53%) were deemed high risk by the 0.3 cut-
off. Using the 0.3 cutoff for risk assessment by MSKPN
risk was not significantly associated with any survival
endpoint in the whole cohort; neither was the non-
dichotomized predicted 4-year death probability (HR,
95% CI, Wald test P: 2.61, 0.69–9.96, P = 0.16 for OS;
2.41, 0.44–13.38, P = 0.31 for RFS; and 3.17, 0.44–23.15,
P = 0.25 for DSS). When evaluated among the non AC
patients, the KM curves showed a trend for better OS in
the MSKPN low-risk patients (log rank test P = 0.085)
and the median survival time was estimated to be
6.58 years (95% CI: 3.13-Inf), and 3.06 (95% CI: 2.33–
5.42), low- and high-risk patients, respectively.
The individual variables incorporated in MSKPN were
prognostic of survival. Evaluated among non-adjuvant
treated patients only, age is significantly associated with
OS with a HR of 1.03 (95% CI: 1.01–1.04, P = 0.0014)
but not with RFS or DSS (HR = 1.01, 0.99–1.02, P = 0.57
and 1.02, 0.99–1.04, P = 0.20, respectively); histology was
found to be prognostic for OS and RFS (log-rank test
P = 0.009 and 0.004, respectively), tumor size was prog-
nostic for RFS (log-rank test P = 0.034).
Choice of I/Epi
Since ifosfamide is rarely recommended for patients older
than 65 years in our practice, the choice of chemotherapy
was highly associated with age (Table 1). Patients receiv-
ing I/Epi were 12.51 years younger than non-adjuvant-
treated patients (mean = 45.91 vs. 58.41, 95% CI on the
mean difference: 6.04–18.96, t-test P = 0.0003). Tumor
depth and histology were also significantly associated with
treatment (Table 1). Among histology types, seven of
eight synovial tumors received I/Epi, while the majority
of other histology subtypes received no chemotherapy
(Fisher’s exact test P = 1.31E-05). Other patient or tumor
characteristics were not significantly associated with treat-
ment (Table 1). The median MSKPN predicted 4-year
postoperative probability of sarcoma-specific death was
0.30 (range 0.15–0.73) in I/Epi-treated versus 0.31 (range
0.07–0.8) in non AC patients, not significant (Wilcoxon
rank sum test P = 0.63). By the 0.3 cutoff, 18 (25%) of
72 high-risk patients and 15 (24%) of 63 low-risk patients
received I/Epi (Fisher’s exact test P = 1). Thus, the choice
of I/Epi over no AC was not significantly associated with
MSKPN-predicted risk reflecting the number of second
opinion referrals at Washington University. The age dif-
ference between I/Epi-treated and non-adjuvant-treated
patients was significant even after stratification by
MSKPN. The mean age of I/Epi-treated patients was
48.5 years among high-risk patients, (62.83 in non-treated
high-risk patients, 95% CI on the mean differ-
ence = 5.13–23.54; t-test P = 0.004) and 42.8 years
among low-risk patients (53.44 years in non AC low-risk
patients, 95% CI on the mean difference = 1.30–19.97; t-
test P = 0.035).
Patients who received I/Epi tended to receive radiation.
Twenty-eight (84.85%) of the 33 I/Epi-treated patients
received radiation, higher than those in the non-treated
patients (55.89%, Fisher’s exact test P = 0.0033, Table 1).
Patients who had radiation showed better survivals in the
whole cohort (log rank test P = 0.043, 0.034, 0.073 for
OS, RFS, and DSS, respectively). Since radiation did not
demonstrate an overall survival benefit in the non-adju-
vant-treated patients (log-rank test P = 0.355, 0.287,
0.394 for OS, RFS, and DSS, respectively), the overall sur-
vival benefit in the high-risk patients can likely be attrib-
uted to I/Epi treatment by using IPTW modeling.
The propensity score methods [19] were applied to
model the likelihood of receiving I/Epi using multivariate
Firth logistic regression model [20]. Initially, a full model
including all available covariates (age, radiation, histology,
MSKPN binary risk, tumor size, race, gender, site, depth,
tumor stage, and margin) was fit followed by backward
selection procedure to arrive at a final logistic regression
model with the four covariates: age, radiation, histology,
and MSKPN binary risk (Table 2). Histology was a strong
influential factor (likelihood ratio test P = 0.0011), but
treatment administration was variable by histological sub-
type. High-risk patients had a higher likelihood of receiv-
ing chemotherapy, although not statistically significant at
Table 2. Multivariate logistic regression model for likelihood of
receiving I/Epi.
Variable Odds ratio (95% CI) P-value
Age at diagnosis 0.94 (0.9–0.97) 0.0004
Radiation (yes vs. no) 11 (2.76–60.63) 0.0002
Histology 0.0011
Liposarcoma versus leiomyosarcoma 3.8 (0.91–17.78) 0.068
Ups versus leiomyosarcoma 0.52 (0.13–2.07) 0.35
Mpnst versus leiomyosarcoma 4.4 (0.85–25.05) 0.078
Synovial versus leiomyosarcoma 22 (2.18–410.58) 0.0069
Fibrosarcoma versus leiomyosarcoma 0.98 (0.01–26.63) 0.99
Other versus leiomyosarcoma 0.26 (0–2.94) 0.32
Risk (high vs. low) 2.4 (0.76–8.55) 0.14
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the 5% level reflecting the number of patients seen in sec-
ond opinion. The propensity scores, that is the predicted
probability of receiving I/Epi was calculated from the final
logistic model and boxplot on the scores (Fig. 1B) by
actual treatment assignment indicated that the model well
captured the likelihood of receiving I/Epi.
Effect of chemotherapy in STS patients
We evaluated the influence of treatment (I/Epi or no AC)
on survival using a propensity score IPTW method in the
context of survival analysis, where the weight on patients
were calculated as inverse to the predicted probabilities of
receiving their assigned treatments to reduce potential
selection bias. Plotted in Figure 2 are the KM curves and
the 5-year absolute survival probability by treatment esti-
mated on the IPTW cohort in comparison to the original
cohort where all subjects had an equal weight of 1.
Chemotherapy was associated with an improved 5-year
survival probabilities from 47% to 81%, 53% to 91%,
and 69% to 92% for OS, RFS, and DSS, respectively, with
absolute differences ranging from 23% to 38%. By Cox
regression modeling, hazards of dying (general or disease-
specific) and relapsing were dramatically higher when
patients were not treated with chemotherapy (Table 3).
The HRs estimated on the IPTW cohort were slightly
smaller compared to the estimates on original cohort for
RFS and DSS but increased for OS. The OS benefit dem-
onstrated in this retrospective study is much higher than
the Italian study, which can be attributed to risk assess-
ment, inclusion of sites other than extremity, retrospec-
tive approach, and/or small sample size.
When treatment was investigated under stratification of
MSKPN risk, both high- and low-risk patients benefited
from adjuvant I/Epi, however, high-risk patients demon-
strated a much greater benefit. The resulting hazard ratios
(I/Epi vs. no-AC) were much higher in high-risk patients
for all the survival outcomes (Table 3), although the dif-
ferences were not significant (Wald test P = 0.16, 0.66,
and 0.44 for OS, RFS, and DSS, respectively). Examining
the 5-year survival probabilities, significant benefit for
I/Epi was found in both high- and low-risk groups
(Fig. 2E–H). The need for stratification of patients into
high-risk and low-risk groups may begin to explain the
difficulty in seeing overall survival differences when all-
comers are used in clinical trials.
To evaluate whether treatment improved survival when
considering the influential clinico-pathological variables
and adjusting for the propensity scores to reduce treat-
ment selection bias, we applied multivariate Cox models
on the propensity score IPTW cohort for all survival end-
points (Table 4). The adjusted HR of treatment
(untreated vs. I/Epi) was 4.18 (95% CI: 2.22–7.90), 8.96
(95% CI: 3.85–20.83), and 5.42 (95% CI: 2.09~14.06) for
OS, RFS, and DSS (Table 4), respectively, indicating a
strong independent influence of adjuvant treatment with
I/Epi on survival in addition to all other variables in the
model. Radiation therapy and depth did not show signifi-
cant HRs when treatment and other variables were
included, while age, histology, and tumor size were signif-
icantly associated with at least one survival endpoint.
Discussion
AC for resectable STS remains controversial and the sub-
ject of adamant debate. Given Washington University’s
use of adjuvant I/Epi, we undertook a retrospective analy-
sis of 33 I/Epi-treated and 102 non-adjuvant-treated
patients. Overall, we found I/Epi corresponded to signifi-
cant improved DSS, OS, and RFS with greatest benefit
among patients at high risk of recurrence.
Our analysis revealed no significant difference in the
median MSKPN-predicted risk between adjuvant I/Epi-
treated versus non-treated patients. However, 46% of
patients receiving I/Epi were of low risk. This is a result
of patients captured in the data set that were seen as sec-
ond opinions. To remove potential influence of I/Epi
treatment, we independently analyzed all 102 patients
who received no-AC and identified a trend of improved
OS in MSKPN predicted low- versus high-risk patients
(log-rank test P = 0.085). Among the MSKPN individual
prognostic variables [15], histology and tumor size
showed significant prognosis effect in our data. These
findings may have been influenced by including only
high-grade STS, a relatively small sample size, and using a
4-year predicted probability of sarcoma-specific death.
To evaluate whether adjuvant I/Epi treatment improved
survival while reducing potential bias from treatment
selection, we implemented the propensity score IPTW
approach in the context of KM analysis and Cox models
to alleviate the limitations of this retrospective study.
When we compared the 5-year survival probability
between I/Epi versus non-adjuvant-treated patients, we
found a difference of 28%, 44%, and 46% for DSS, OS,
and RFS in high-risk patients, and a smaller difference in
low-risk patients.
Adjuvant radiotherapy is commonly used with close or
positive margins. In our data set, radiation therapy was
given to 85 patients (85% I/Epi-treated versus 56%
untreated) with high-grade STS with margin status (35
positive margins, 18 < 1 cm, 32 > 1 cm) and within a
variable set of histologies. In prospective studies high-
grade STS patients receiving postoperative radiotherapy
demonstrated a lower risk of local recurrence [26]. In our
data set, radiation was associated with improved RFS and
OS, IPTW modeling allows us to attribute the RFS and
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Survival Treatment
5-year survival probability
high risk only low risk only 
OS I/Epi 0.86 (0.77~0.97) 0.75 (0.62~0.91)
No-Adjuvant 0.42 (0.32~0.56) 0.54 (0.42~0.68)
RFS I/Epi 0.9 (0.81~1) 0.92 (0.84~1)
No-Adjuvant 0.44 (0.31~0.62) 0.6 (0.48~0.74)
DSS I/Epi 0.94 (0.88~1) 0.89 (0.79~1)






OS I/Epi 0.81 (0.72~0.9) 0.77 (0.64~0.94)
No-Adjuvant 0.47 (0.39~0.57) 0.45 (0.36~0.57)
RFS I/Epi 0.91 (0.85~0.98) 0.93 (0.85~1)
No-Adjuvant 0.53 (0.44~0.63) 0.51 (0.41~0.64)
DSS I/Epi 0.92 (0.85~0.99) 0.92 (0.82~1)





Figure 2. (A–D) The KM curves of DSS (A), OS (B), and RFS (C) by treatment (IPTW: solid lines; No-adjuvant: dotted lines) in the raw cohort (red
lines) and the IPTW cohort (blue lines) and the associated 5-year survival probability estimations with 95% CI in parenthesis (D); (E–H): The KM
curves of DSS (E), OS (F), RFS (G) by high/low MSKPN risk and treatment combinations using the IPTW cohort and 5-year survival probability
estimations with 95% CI in parenthesis (H).
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OS to AC in high-risk patients, as patients who received
radiation were more likely to receive AC. Prior trials of
AC in STS have ranged in size from approximately 43 to
245 patients (Mean = 100) [7, 27]. Interestingly, the 5-
year OS probability for the non AC group was 0.46 in the
Italian study [7], similar to our population (0.47). In our
I/Epi-treated group, the OS probability was 0.81 versus
0.66 in the Italian study [7]. However, the Italian study
selected only high-grade extremity STS, while our analysis
analyzed all primary locations.
Despite the dominance of doxorubicin-based AC in
other studies, these data support epirubicin as a viable
alternative, as originally demonstrated by Frustaci et al.
[7]. Despite our attempts to mitigate selection bias through
a propensity IPTW method, these data are hypothesis gen-
erating only. The large number of STS histologies and vari-
ation in the use of neoadjuvant or AC between centers
suggests revisiting the use of epirubicin as part of adjuvant
therapy. This could be achieved through a randomized trial
through a cooperative group or consortium, where stratifi-
cation by histology, biomarker, or genetic signature could
be performed. Without further primary data, the field will
be left with unanswered questions regarding the best agents
for neoadjuvant or adjuvant therapy and who, if anyone,
would benefit most. Although this trial will be costly and
difficult to fund, the importance of AC for sarcoma still
needs to be addressed.
Finally, epirubicin dosing has not been established in
sarcoma where higher dosing can be used with less risk of
cardiotoxicity [28]. Although Lopez et al. showed a higher
response rate at higher dosing of epirubicin [29], the AC
epirubicin total dosing of 600 mg/m2 [7] compares to the
breast cancer clinical trial literature, where total cumulative
dosage is between 360 mg/m2 and 800 mg/m2 [30]. The
opportunity to increase the total cumulative dosage above
600 mg/m2 [7] may also be warranted in a clinical trial set-
ting to try to improve outcomes.
In summary, within the limits of our retrospective
analysis, I/Epi-treated patients regardless of their MSKPN
risk of relapse have a significantly greater OS, RFS, and
DSS compared to those not receiving AC. Therefore, ran-
domized, appropriately powered, prospective clinical
investigations are warranted to further investigate if I/Epi
is superior to I/Doxorubicin for AC in STS.
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Table 4. Multivariate Cox regression model in the IPTW cohort.
Variable
OS RFS DSS
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Treatment (no-adjuvant vs. I/Epi) 4.18 (2.22–7.9) 1.0E-05 8.96 (3.85–20.83) 3.5E-07 5.42 (2.09–14.06) 0.0005
Age at diagnosis 1.02 (1.01–1.04) 0.008 1.0 (0.98–1.02) 0.86 1.01 (0.99–1.04) 0.30
Histology 1.1E-06 0.0003 0.078
Liposarcoma versus leiomyosarcoma 0.96 (0.49–1.88) 0.90 0.17 (0.07–0.42) 9.1E-05 0.32 (0.11–0.91) 0.032
Mfh versus leiomyosarcoma 1.4 (0.76–2.59) 0.28 0.46 (0.24–0.87) 0.018 0.87 (0.38–2.02) 0.75
Mpnst versus leiomyosarcoma 0.27 (0.08–0.90) 0.034 0.21 (0.07–0.6) 0.0035 0.39 (0.11–1.34) 0.14
Other versus leiomyosarcoma 2.82 (1.32–6.02) 0.0075 0.19 (0.04–0.79) 0.022 0.6 (0.13–2.66) 0.50
Synovial versus leiomyosarcoma 7.91 (2.94–21.24) 4.1E-05 0.0009 (0–Inf) 0.56 2.32 (0.48–11.26) 0.30
Fibrosarcoma versus leiomyosarcoma 9.47 (2.05–43.80) 0.0040 1.44 (0.17–11.94) 0.73 3.73 (0.38–36.59) 0.26
Radiation (yes vs. no) 0.92 (0.58–1.47) 0.74 0.72 (0.4–1.29) 0.27 0.74 (0.38–1.43) 0.37
Risk (high vs. low) 1.09 (0.6–1.97) 0.78 0.74 (0.36–1.51) 0.41 0.86 (0.36–2.09) 0.74
Depth (superficial vs. deep) 0.96 (0.42–2.17) 0.92 0.62 (0.18–2.16) 0.45 1.09 (0.29–4.09) 0.90
Tumor size 0.16 0.11 0.067
5~10 versus ≤5 1.36 (0.65–2.84) 0.42 2 (0.77–5.23) 0.16 1.52 (0.47–4.94) 0.49
>10 versus ≤5 1.9 (0.91–3.98) 0.087 2.69 (1.05–6.92) 0.040 3.01 (0.95–9.59) 0.062
Table 3. Univariate Cox regression model evaluating treatment effect in the IPTW cohort, overall and then by MSKPN risk.
Survival
All patients (N = 135) High risk patients (N = 72) Low risk patients (N = 63)
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
OS 4.43 (2.53–7.76) 1.9E-07 6.94 (2.96–16.29) 8.4E-06 2.91 (1.37–6.18) 0.0054
RFS 8.02 (3.57–18.05) 4.8E-07 9.54 (3.16–28.77) 6.2E-05 6.51 (1.97–21.55) 0.0022
DSS 5.57 (2.29–13.53) 0.00015 8.2 (2.26–29.68) 0.0013 3.82 (1.11–13.13) 0.033
Hazard ratios (HRs) refer to non AC versus I/Epi.
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